GLPBio

NMDI14

Catalog No.: GC32744Purity:>98.00%
NMDI14 ist ein Inhibitor des Nonsense-vermittelten RNA-Zerfalls (NMD). NMDI14 unterbricht die SMG7-UPF1-Interaktionen und hemmt NMD.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.


NMDI14
Cas No.: 307519-88-6
1mgIn Stock
$24.00
1
5mgIn Stock
$69.00
1
10mgIn Stock
$123.00
1
25mgIn Stock
$263.00
1
50mgIn Stock
$382.00
1

Zitate (Citations)

Für dieses Produkt sind derzeit keine Zitate verfügbar. Nachfolgend finden Sie ausgewählte Publikationen, die GlpBio-Produkte zitieren.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Beschreibung (Description)

NMDI14 is potent inhibitor of nonsense mediated RNA decay (NMD)[1]. NMDI14 prevents the formation of the UPF1-SMG7 (or UPF1-SMG5) heterodimers, suppresses NMD and stabilizes W1282X mRNA [2]. NMDI14 has been widely used as a model compound to develop a series of derivatives and serve as anti-mesothelioma agents in vitro[3].

In vitro, NMDI14 treatment at 50μM for 6 hours significantly increased the expression level of p53 mRNA in U2OS cells, without affecting cell viability[4]. After treating primary nasal epithelial cells of W1282X heterozygous carriers with 5μM NMDI14 for 12 hours, the level of W1282X transcripts was significantly increased[5]. Treatment with 50 μM NMDI14 for 72 hours can prevent the upregulation of ABCC1 and ABCC2 mRNA mediated by human papilloma virus (HPV) 18 E6/E7 proteins in HNO206 cells[6]. 0.1μM of NMDI14 and CC-90009 (7.5nM) treatment for 2 days significantly promoted the increase in the expression of type XVII collagen in JEB-C17 keratinocytes without affecting cell viability[7].

In, vivo, NMDI14 treatment via intracerebroventricular injection (2μL; 674 μM) three times within 24h in a mouse model of status epilepticus significantly reduced the spontaneous epileptic seizures that occurred following the persistent state of epilepsy[8].

References:
[1] Evtushenko N, Beilin A, Novikov A, et al. 163 Nonsense-mediated mRNA decay inhibitors perspectives for recessive dystrophic epidermolysis bullosa treatment[J]. Journal of Investigative Dermatology, 2021, 141(10): S176.
[2] Ensinck M M, Carlon M S. One size does not fit all: the past, present and future of cystic fibrosis causal therapies[J]. Cells, 2022, 11(12): 1868.
[3] Nguyen H N, Suzuki K, Kimura Y, et al. Synthesis and biological evaluation of NMDI14 derivatives as anti-mesothelioma agents[J]. Heterocycles, 2020, 100(2): 253-266.
[4] Martin L, Grigoryan A, Wang D, et al. Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations[J]. Cancer research, 2014, 74(11): 3104-3113.
[5] Aksit M A, Bowling A D, Evans T A, et al. Decreased mRNA and protein stability of W1282X limits response to modulator therapy[J]. Journal of Cystic Fibrosis, 2019, 18(5): 606-613.
[6] Rigalli J P, Reichel M, Tocchetti G N, et al. Human papilloma virus (HPV) 18 proteins E6 and E7 up-regulate ABC transporters in oropharyngeal carcinoma. Involvement of the nonsense-mediated decay (NMD) pathway[J]. Cancer letters, 2018, 428: 69-76.
[7] Sayar S B, Has C. Strategy for the optimization of read-through therapy for junctional epidermolysis bullosa with COL17A1 nonsense mutation[J]. Journal of Investigative Dermatology, 2024, 144(10): 2221-2229. e1.
[8] Mooney C M, Jimenez-Mateos E M, Engel T, et al. RNA sequencing of synaptic and cytoplasmic Upf1-bound transcripts supports contribution of nonsense-mediated decay to epileptogenesis[J]. Scientific reports, 2017, 7(1): 41517.

Protokoll (Protocol)

Cell experiment [1]:

Cell lines

U2OS cells

Preparation Method

U2OS cells were cultured in DMEM medium containing 10% fetal bovine serum. The cells were seeded in 6-well plates and after 24 hours, they were treated with NMDI14 (50μM) for 6 hours, and the expression of endogenous unmutated NMD targets was evaluated by real-time PCR.

Reaction Conditions

50μM; 6h

Applications

NMDI14 treatment significantly enhanced the expression of p53 mRNA in U2OS cells.
Animal experiment [2]:

Animal models

Male C57BL/6 mice

Preparation Method

Anesthetize male C57BL/6 mice with isoflurane and place them in a stereotactic frame, which is equipped with cranial-mounted recording electrodes. Perform a craniotomy and place a guiding catheter above the right amygdala of the skull. Secure the components in place, then place the mouse in a warm recovery room. Next, using the catheter, microinject KA (0.3 μg; 0.2μl) into the right amygdala of the freely moving mouse. Seizures begin within 5-10 minutes and progressively worsen, becoming persistent epilepsy after approximately 30 minutes. 40 minutes after the KA seizure, administer lorazepam (8mg/kg; intraperitoneal injection) to reduce morbidity and mortality and limit the degree of hippocampal damage. Additional craniotomies were performed during the intracranial injection of the electrodes and guiding catheters. At 1, 4, and 24 hours after the lorazepam termination of the seizures, inject NMDI14 (2μl; 674 μM) into the ventricles, achieving a final ventricular NMDI14 concentration of approximately 50μM, for continuous video electroencephalogram monitoring of the mice.

Dosage form

2μl 674 μM three times a day for 1 day; i.c.v

Applications

NMDI14 treatment reduced spontaneous epileptic seizures after status epilepticus in mice.

References:
[1] Martin L, Grigoryan A, Wang D, et al. Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations[J]. Cancer research, 2014, 74(11): 3104-3113.
[2] Mooney C M, Jimenez-Mateos E M, Engel T, et al. RNA sequencing of synaptic and cytoplasmic Upf1-bound transcripts supports contribution of nonsense-mediated decay to epileptogenesis[J]. Scientific reports, 2017, 7(1): 41517.

Produktdokumente (Product Documents)

Purity:>98.00%Appearance:A solid

Chemische Eigenschaften (Chemical Properties)

CAS-Nr.
307519-88-6
SMILES
O=C(C1=C(NC(CC2NC3=C(C=C(C)C(C)=C3)NC2=O)=O)SC(C)=C1C)OCC
Summenformel
C21H25N3O4S
Molekulargewicht
415.51
Löslichkeit
DMSO : ≥ 25 mg/mL (60.17 mM)
Lagerung
Store at -20°C
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for NMDI14

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%